您的位置: 首页 > 农业专利 > 详情页

COMBINATION OF DIRECT EFFECTIVE ANTIVIRAL AGENTS AND RIBAVIRIN FOR TREATMENT OF HCV PATIENTS
专利权人:
AbbVie Inc.
发明人:
BERNSTEIN, Barry M.,DUTTA, Sandeep,LIU, Wei,PODSADECKI, Thomas J.,CAMPBELL, Andrew L.,MENON, Rajeev M.,LIN, Chih-Wei,WANG, Tianli,AWNI, Walid M.,MENSING, Sven
申请号:
DK14725812
公开号:
DK2968302T3
申请日:
2014.03.14
申请国别(地区):
DK
年份:
2017
代理人:
摘要:
The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents and ribavirin to a subject with HCV infection, wherein the treatment lasts for 12 weeks and does not include administration of interferon, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof.
来源网站:
中国工程科技知识中心
来源网址:
http://www.ckcest.cn/home/

意 见 箱

匿名:登录

个人用户登录

找回密码

第三方账号登录

忘记密码

个人用户注册

必须为有效邮箱
6~16位数字与字母组合
6~16位数字与字母组合
请输入正确的手机号码

信息补充